Importer of Controlled Substances Application: Fresenius Kabi USA, LLC, 34878-34879 [2018-15750]
Download as PDF
<![CDATA[
34878
Federal Register / Vol. 83, No. 141 / Monday, July 23, 2018 / Notices
defined the term ‘‘practitioner’’ to mean
‘‘a physician . . . or other person
licensed, registered, or otherwise
permitted, by . . . the jurisdiction in
which he practices . . . , to distribute,
dispense, . . . [or] administer . . . a
controlled substance in the course of
professional practice.’’ 21 U.S.C.
802(21). Second, in setting the
requirements for obtaining a
practitioner’s registration, Congress
directed that ‘‘[t]he Attorney General
shall register practitioners . . . if the
applicant is authorized to dispense . . .
controlled substances under the laws of
the State in which he practices.’’ 21
U.S.C. 823(f). Because Congress has
clearly mandated that a practitioner
possess State authority in order to be
deemed a practitioner under the CSA,
the DEA has held repeatedly that
revocation of a practitioner’s registration
is the appropriate sanction whenever he
is no longer authorized to dispense
controlled substances under the laws of
the State in which he practices. See,
e.g., Hooper, supra, 76 FR at 71,371–72;
Sheran Arden Yeates, M.D., 71 FR
39,130, 39,131 (2006); Dominick A.
Ricci, M.D., 58 FR 51,104, 51,105 (1993);
Bobby Watts, M.D., 53 FR 11,919, 11,920
(1988); Blanton, supra, 43 FR at 27,617.
According to Mississippi statute,
‘‘Every person who desires to practice
dentistry . . . in this state must obtain
a license to do so.’’ Miss. Code Ann.
§ 73–9–1 (West, Westlaw current with
laws from the 2018 Regular Session).
Further, ‘‘[e]very person who . . .
dispenses any controlled substance
within this state . . . must obtain a
registration issued by . . . the State
Board of Dental Examiners . . . in
accordance with its rules and the law of
this state.’’ Miss. Code Ann. § 41–29–
125(1)(a) (West, Westlaw current with
laws from the 2018 Regular
Session).3 See also Miss. Code Ann.
§ 73–9–53 (West, Westlaw current with
laws from the 2018 Regular Session)
(authorizing Mississippi pharmacists to
fill prescriptions only of ‘‘legally
licensed and registered dentists of this
state for any drugs to be used in the
practice of dentistry’’) and Miss. Admin.
Code 30–2301:1.35(1) (West, current
through the Mississippi Administrative
Rules Listing of Filings, dated May
2018) (legally licensed and registered
dentists may write prescriptions for any
drugs to be used in the practice of
dentistry).
Here, the undisputed evidence in the
record is that Registrant currently lacks
authority to practice dentistry and
handle controlled substances in
Mississippi. As already discussed, only
a legally licensed and registered dentist
may dispense a controlled substance or
any drug to be used in the practice of
dentistry in Mississippi. Thus, since
Registrant lacks authority to practice
dentistry in Mississippi, and is not
registered in Mississippi to handle
controlled substances, I will order that
Registrant’s DEA registration be
revoked.
comments on or objections to the
issuance of the proposed registration on
or before August 22, 2018. Such persons
may also file a written request for a
hearing on the application on or before
August 22, 2018.
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
ADDRESSES:
Order
SUPPLEMENTARY INFORMATION:
Pursuant to 28 CFR 0.100(b) and the
authority thus vested in me by 21 U.S.C.
824(a), I order that DEA Certificate of
Registration No. FB0508993 issued to
Kenneth C. Beal, Jr., D.D.S., be, and it
hereby is, revoked. This Order is
effective August 22, 2018.
The Attorney General has delegated
his authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on June
21, 2018, Fresenius Kabi USA, LLC,
3159 Staley Road, Grand Island, New
York 14072–2028 applied to be
registered as an importer of the
following basic class of controlled
substance:
Dated: July 9, 2018.
Uttam Dhillon,
Acting Administrator.
[FR Doc. 2018–15743 Filed 7–20–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Fresenius Kabi USA, LLC
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
DATES:
Drug code
Schedule
Remifentanil .............................................................................................................................................................
amozie on DSK3GDR082PROD with NOTICES1
Controlled substance
9739
II
3 ‘‘Dispensing’’ a controlled substance includes
‘‘prescribing’’ and ‘‘administering’’ it. Miss. Code
VerDate Sep<11>2014
17:59 Jul 20, 2018
Jkt 244001
Ann. § 41–29–105(j) (West, Westlaw current with
laws from the 2018 Regular Session).
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
E:\FR\FM\23JYN1.SGM
23JYN1
34879
Federal Register / Vol. 83, No. 141 / Monday, July 23, 2018 / Notices
The company plans to import the
listed controlled substance for narcotic
material for bulk manufacture.
Dated: July 12, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–15750 Filed 7–20–18; 8:45 am]
BILLING CODE 4410–09–P
In accordance with 21 CFR
1301.34(a), this is notice that on April
23, 2018, Shertech Laboratories, LLC,
1185 Woods Chapel Road, Duncan
South Carolina 29334 applied to be
registered as an importer of the
following basic class of controlled
substance:
Drug
Code
Controlled substance
DEPARTMENT OF JUSTICE
Cocaine ........................
9041
Schedule
II
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Applications: Shertech Laboratories,
LLC
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 22, 2018. Such persons
may also file a written request for a
hearing on the application on or before
August 22, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
amozie on DSK3GDR082PROD with NOTICES1
DATES:
VerDate Sep<11>2014
19:07 Jul 20, 2018
Jkt 244001
The company plans to import
synthetic derivatives of the listed
controlled substance in bulk form to
conduct clinical trials.
Approval of permit applications will
occur only when the registrant’s activity
is consistent with what is authorized
under to 21 U.S.C.952 (a)(2).
Authorization will not extend to the
import of FDA approved or nonapproved finished dosage forms for
commercial sale.
Dated: July 12, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–15713 Filed 7–20–18; 8:45 am]
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on June 5,
2018, Fisher Clinical Services, 700A–C
Nestle Way, Breinigsville, PA 18031–
1522 applied to be registered as an
importer of the following basic class of
controlled substance:
BILLING CODE 4410–09–P
Controlled substance
Drug
code
Schedule
DEPARTMENT OF JUSTICE
Psilocybin .....................
Drug Enforcement Administration
The company plans to import the
listed controlled substance for clinical
trials.
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Fisher Clinical Services,
Inc.
ACTION:
Notice of application.
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
I
Dated: July 12, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–15667 Filed 7–20–18; 8:45 am]
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 22, 2018. Such persons
may also file a written request for a
hearing on the application on or before
August 22, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
DATES:
7437
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration
ACTION:
Notice of registration.
The registrant listed below
has applied for and been granted
registration by the Drug Enforcement
Administration (DEA) as an importer of
various classes of schedule I or II
controlled substances.
SUPPLEMENTARY INFORMATION:
The company listed below applied to
be registered as an importer of various
basic classes of controlled substances.
Information on the previously published
notice is listed in the table below. No
comments or objections were submitted
SUMMARY:
E:\FR\FM\23JYN1.SGM
23JYN1
]]>Agencies
[Federal Register Volume 83, Number 141 (Monday, July 23, 2018)]
[Notices]
[Pages 34878-34879]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-15750]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Fresenius Kabi
USA, LLC
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before August 22, 2018.
Such persons may also file a written request for a hearing on the
application on or before August 22, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
request for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION:
The Attorney General has delegated his authority under the
Controlled Substances Act to the Administrator of the Drug Enforcement
Administration (DEA), 28 CFR 0.100(b). Authority to exercise all
necessary functions with respect to the promulgation and implementation
of 21 CFR part 1301, incident to the registration of manufacturers,
distributors, dispensers, importers, and exporters of controlled
substances (other than final orders in connection with suspension,
denial, or revocation of registration) has been redelegated to the
Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on June
21, 2018, Fresenius Kabi USA, LLC, 3159 Staley Road, Grand Island, New
York 14072-2028 applied to be registered as an importer of the
following basic class of controlled substance:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Remifentanil.......................... 9739 II
------------------------------------------------------------------------
[[Page 34879]]
The company plans to import the listed controlled substance for
narcotic material for bulk manufacture.
Dated: July 12, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-15750 Filed 7-20-18; 8:45 am]
BILLING CODE 4410-09-P
